FDA Accepts For Priority Review Supplemental Biologics License Application For Pfizer’s 20-Valent Pneumococcal Conjugate Vaccine For Use In Infants, Children

January 09, 2023

Healio (1/6) reported, “The FDA has accepted for priority review a supplemental biologics license application for Pfizer’s 20-valent pneumococcal conjugate vaccine for use in infants and children aged 6 weeks to 17 years, Pfizer announced.” This “20-valen...